Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma 2982Precursor Cell Lymphoblastic Leukemia-Lymphoma 2499Lymphoma, Non-Hodgkin 2268Leukemia, Lymphocytic, Chronic, B-Cell 1992Lymphoma, Follicular 1847Lymphoma, Large B-Cell, Diffuse 1785Leukemia 1341Hodgkin Disease 1293Lymphoma, Mantle-Cell 1193Leukemia, Myeloid, Acute 979Burkitt Lymphoma 956Multiple Myeloma 866Lymphoma, B-Cell, Marginal Zone 853Recurrence 841Lymphoma, B-Cell 756Myelodysplastic Syndromes 683Neoplasms 595Lymphoma, T-Cell, Cutaneous 543Waldenstrom Macroglobulinemia 514Lymphoma, Large-Cell, Immunoblastic 490Mycosis Fungoides 438Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 414Lymphoma, Large-Cell, Anaplastic 390Sezary Syndrome 364Lymphoma, T-Cell, Peripheral 352Hematologic Neoplasms 351Leukemia, Myelogenous, Chronic, BCR-ABL Positive 334Myeloproliferative Disorders 328Neoplasms, Plasma Cell 309Blast Crisis 284

Interventions

arginine butyrate 1Valganciclovir 1Ganciclovir 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
EBV Lymphomas × Lymphoid × Clear all
NCT03988582 2020-06-11

Safety and Effectiveness of EBV-specific Cytotoxic T Cells for the Treatment for EBV Lymphomas or Other EBV-associated Malignancies

Memorial Sloan Kettering Cancer Center

Phase 2 Withdrawn
Lymphoid

EBV Lymphomas

NCT00917826 2011-08-01

Study of Arginine Butyrate and Ganciclovir/Valganciclovir in EBV(+) Lymphoid Malignancies

HemaQuest Pharmaceuticals Inc.

Phase 2 Terminated
1 enrolled
Lymphoid

EBV Lymphomas

Data powered by HemOnc (CC BY 4.0) Colophon âš¡